Diagnosing Destabilized Heart Failure in the Emergency Setting

Gruson, Damien; Thys, Frédéric; Verschuren, Franck

doi:10.1007/bf03256468

Cited by 1 publication

(2 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have investigated the effects of various drug candidates on T2D and its complications, including liver fibrosis. 37 , 38 In our study, L6H4 treatment of T2D rats for almost 2 months significantly increased their body weight and MMP-2 expression in the liver. It also significantly decreased collagen deposition in the liver and various parameters, such as ALT, AST, FPG, HOMA-IR, FINS, TC, LDL, TGF-β1, and TIMP-2.…”

Section: Discussionsupporting

confidence: 59%

“…have been shown to ameliorate liver fibrosis by inhibiting TGF-β, our study is the first to describe the changes in MMP-2 and TIMP-2 levels in the liver before and after curcumin (analogue) treatment of T2D. 33,34,[36][37][38][39] There is growing interest in using natural products like curcumin to treat NAFLD due to their efficacy, availability, low cost, and minimal side effects as compared to pharmaceutical drugs, as evidenced by recent preclinical and clinical studies. Given curcumin's potential, our study provides evidence that its synthetic analog L6H4 effectively treats complications of T2D like liver fibrosis by modulating key markers like MMP-2 and TIMP-2.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Novel Curcumin Analogue L6H4 in Treating Liver Fibrosis and Type 2 Diabetes

Ma,

Vaishnani,

Mansi

et al. 2023

DMSO

View full text Add to dashboard Cite

Purpose The objective of this study was to evaluate the therapeutic efficacy of the curcumin analogue L6H4 in attenuating liver fibrosis and alleviating insulin resistance in streptozotocin-induced diabetic rats. Methods Male Sprague-Dawley rats were fed a high-fat diet to induce insulin resistance, followed by streptozotocin injection to induce diabetes. The rats were then treated with L6H4 for eight weeks. Body weight, metabolic parameters, liver function, and liver histopathology were evaluated. Immunohistochemistry was performed to assess the expression of TGF-β1, TIMP-2, and MMP-2 in liver tissues. Statistical analysis was conducted using one-way ANOVA and Spearman rank correlation test. Results L6H4 treatment effectively reversed the weight gain associated with a high-fat diet and improved metabolic parameters in diabetic rats. Liver function markers, such as ALT and AST, were reduced after L6H4 treatment. Histological analysis showed improved liver morphology and reduced fibrosis in L6H4-treated rats. Electron microscopy revealed improved ultrastructural features of hepatocytes. Immunohistochemistry demonstrated downregulation of TGF-β1 and TIMP-2 expression and restoration of MMP-2 expression in the liver tissue of L6H4-treated rats. Correlation analysis showed a significant positive correlation between TGF-β1 and TIMP-2 expression. Conclusion The findings suggest that L6H4 has therapeutic potential in attenuating liver fibrosis and alleviating insulin resistance in streptozotocin-induced diabetic rats. The hepatoprotective effect of L6H4 may be attributed to its anti-inflammatory properties and its ability to target molecules involved in fibrosis. Further research is warranted to explore the potential of L6H4 as a treatment option for nonalcoholic fatty liver disease and type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 59%